Skip to content
10-Q

Quarterly Report

ESTRELLA IMMUNOPHARMA, INC. ESLA ESLAW

0001213900-25-043365

← back to feed
Filed
May 14, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 13, 2025 36.17M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $421.47K
Cash And Equivalents Q1 2025 · Dec 31, 2024 $916.92K
Current Liabilities Q1 2025 · Mar 31, 2025 $4.28M
Current Liabilities Q1 2025 · Dec 31, 2024 $3M
Total Liabilities Q1 2025 · Mar 31, 2025 $4.28M
Total Liabilities Q1 2025 · Dec 31, 2024 $3M
Current Assets Q1 2025 · Mar 31, 2025 $944.27K
Current Assets Q1 2025 · Dec 31, 2024 $1.64M
Total Assets Q1 2025 · Mar 31, 2025 $2.44M
Total Assets Q1 2025 · Dec 31, 2024 $3.14M
Shares Diluted Q1 2025 · Mar 31, 2024 35.52M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$4.23M
Stockholders Equity Q1 2025 · Mar 31, 2024 $8.49M
Stockholders Equity Q1 2025 · Dec 31, 2023 $9.05M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.01
Eps Basic Q1 2025 · Mar 31, 2024 −$0.01
Sga Expense Q1 2025 · Mar 31, 2024 $444.53K
Rd Expense Q1 2025 · Mar 31, 2024 $25K
Net Income Q1 2025 · Mar 31, 2024 −$469.53K
Operating Income Q1 2025 · Mar 31, 2024 −$469.53K